The potential for local ablative therapy of oligometastases in head and neck squamous cell carcinoma: a real-world data analysis

Figures & data

Figure 1. Flowchart showing the selection of candidates for local ablative therapy of pharynx and larynx squamous cell carcinomas. RT; radiotherapy, DM; distant metastases, SBRT; stereotactic body radiation therapy. Created in lucidchart, www.lucidchart.com.

Table 1. Patient and characteristics of distant metastases.

Patient and DM characteristicsa	OMD		PMD
	(N = 57)		(N = 67)
	No. patients	%	No. patients	%
Subsite
Oropharynx	27	47	38	57
p16/HPV+	11	19	23	34
p16/HPV–	15	26	12	18
Hypopharynx	18	32	17	25
Nasopharynx	4	7	3	4
Larynx	8	14	9	13
Stageb
I-II	7	12	2	3
III-IV	50	88	65	97
Smoking
Never	7	12	6	9
Current/former	49	86	59	88
Symptomatic DM
Yes	21	37	49	73
No	35	61	15	22
Number of organs with DM
1	49	86	16	24
2	8	14	27	40
3	0	0	16	24
≥4	0	0	8	12
Localization of DMc
Lung (±pleura)	41	72	56	84
Bone	10	18	25	37
Liver	4	7	18	27
Lymph nodes	11	19	28	42
Other (brain, peritoneum, and skin)	0	0	22	33
Number of metastases
1	30	53	0	0
2	11	19	0	0
3	10	18	0	0
4	5	9	0	0
5	1	2	0	0
Multiple (>5)	0	0	67	100
DM treatment intentd
Palliative intent	39	68	67	100
Radical intent	18	32	0	0

^aMissing values are not depicted if less than 5% of total.

^bAmerican Joint Comitee on Cancer 7th edition.

^cMore than one organ can be involved in the DM, so the sum of proportions exceeds 100.

^dPalliative intent includes patients treated with disease-specific treatment or patients treated with supportive care.

OMD: oligometastatic disease, PMD: polymetastatic disease.

Figure 2. Kaplan-Meier Curves displaying the overall survival of patients with polymetastatic disease, non-radically treated (PMD, N = 67), and patients with oligometastatic disease (OMD, N = 39, non-radically treated, N = 18, radically treated), respectively. The observed time is from date of distant metastasis diagnosis (after definitive, primary treatment) to death or end of follow-up.